Brief: Guard Therapeutics To Expand Phase 2 Study Of Rosgard To Canada

Disruptive Pharma AB (publ)

12/01/2022 15:10

Jan 12 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * GUARD THERAPEUTICS RECEIVES APPROVAL TO EXPAND THE GLOBAL
PHASE
2 STUDY OF ROSGARD TO CANADA
    * THIS GLOBAL STUDY IS PLANNED TO BE CONDUCTED IN EUROPE AND
NORTH
AMERICA AND HAS SINCE EARLIER BEEN APPROVED BY GERMAN MEDICINES
REGULATOR
    * CANADIAN STUDY CENTRES ARE EXPECTED TO CONTRIBUTE
SIGNIFICANTLY
TO OVERALL PATIENT RECRUITMENT, AND STUDY IS PLANNED TO START IN
Q1 OF 2022.

Source text for Eikon:  ID:nMFN4c9jRr 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))